FR04C0014I2 - - Google Patents

Info

Publication number
FR04C0014I2
FR04C0014I2 FR04C0014C FR04C0014C FR04C0014I2 FR 04C0014 I2 FR04C0014 I2 FR 04C0014I2 FR 04C0014 C FR04C0014 C FR 04C0014C FR 04C0014 C FR04C0014 C FR 04C0014C FR 04C0014 I2 FR04C0014 I2 FR 04C0014I2
Authority
FR
France
Prior art keywords
synthesis
disclosed
acid compounds
boronic ester
novel boronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR04C0014C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR04C0014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of FR04C0014I1 publication Critical patent/FR04C0014I1/fr
Application granted granted Critical
Publication of FR04C0014I2 publication Critical patent/FR04C0014I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
FR04C0014C 1994-10-28 2004-05-19 Active FR04C0014I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses
PCT/US1995/014117 WO1996013266A1 (fr) 1994-10-28 1995-10-27 Composes d'esters et d'acides boroniques, leur synthese et leurs utilisations

Publications (2)

Publication Number Publication Date
FR04C0014I1 FR04C0014I1 (fr) 2004-09-17
FR04C0014I2 true FR04C0014I2 (fr) 2005-05-21

Family

ID=26987313

Family Applications (1)

Application Number Title Priority Date Filing Date
FR04C0014C Active FR04C0014I2 (fr) 1994-10-28 2004-05-19

Country Status (24)

Country Link
US (16) US6083903A (fr)
EP (4) EP0788360B3 (fr)
JP (1) JP3717934B2 (fr)
KR (1) KR100398944B1 (fr)
CN (2) CN1305475C (fr)
AT (3) ATE314378T1 (fr)
AU (1) AU710564B2 (fr)
CA (2) CA2203936C (fr)
CH (1) CH0788360H1 (fr)
CY (1) CY2484B1 (fr)
DE (5) DE122004000025I1 (fr)
DK (3) DK0788360T5 (fr)
ES (3) ES2254803T3 (fr)
FI (2) FI114801B (fr)
FR (1) FR04C0014I2 (fr)
IL (5) IL137726A (fr)
LU (1) LU91083I2 (fr)
MX (1) MX9703063A (fr)
NL (1) NL300151I2 (fr)
NO (2) NO310558B1 (fr)
NZ (2) NZ337211A (fr)
PT (3) PT788360E (fr)
TW (1) TW318850B (fr)
WO (1) WO1996013266A1 (fr)

Families Citing this family (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US6271199B2 (en) * 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1017398A1 (fr) * 1997-09-25 2000-07-12 Proscript, Inc. INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-$g(k)B PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES
CA2304206A1 (fr) * 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation de cellules hematopoietiques in vitro
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (fr) * 1997-10-31 1999-04-30 Jiangping Wu Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (fr) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs bivalents de protéasome
BR9914648A (pt) * 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
AU2001287399A1 (en) * 2000-08-16 2002-02-25 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
ATE338564T1 (de) * 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
US6740674B2 (en) 2001-05-21 2004-05-25 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
DE60209227T2 (de) * 2001-05-30 2006-08-17 Novartis Ag 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033507A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
EP1487459A4 (fr) * 2002-03-12 2006-05-24 Ariad Pharma Inc Analogues de peptides et utilisations
OA12793A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
MXPA04008796A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
KR20040093692A (ko) * 2002-03-13 2004-11-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의 피페라지닐-,피페리디닐- 및 모르폴리닐-유도체
DE60326436D1 (en) * 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
DE50313092D1 (de) * 2002-04-05 2010-10-28 Virologik Gmbh Mittel zur behandlung von flaviviridae-infektionen
AU2003243594A1 (en) * 2002-06-13 2003-12-31 Johns Hopkins University Novel boronic chalcone derivatives and uses thereof
US20050084490A1 (en) * 2002-07-09 2005-04-21 Point Therapeutics, Inc. Boroproline compound combination therapy
ES2282658T3 (es) * 2002-08-14 2007-10-16 Janssen Pharmaceutica N.V. Uso de inhibidores de nf-kappa b para el tratamiento de la mastitis.
US7112572B2 (en) * 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
CA2535792A1 (fr) * 2002-09-09 2004-03-18 Trigen Limited Sels d'acide boronique et leur utilisation dans le traitement de la thrombose
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
CA2497977A1 (fr) * 2002-09-20 2004-04-01 Alcon, Inc. Utilisation d'inhibiteurs de la synthese des cytokines dans le traitement des troubles associes a la keratoconjonctivite seche
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
WO2005007211A2 (fr) * 2003-07-03 2005-01-27 Medtronic Vascular Inc. Dispositifs medicaux et compositions destines a l'administration d'inhibiteurs du proteasome sur des sites anatomiques exposes a des maladies vasculaires
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005044998A2 (fr) 2003-11-05 2005-05-19 Palingen, Inc. Cytotoxicite augmentee de l'anticorps de liaison cdim contre les lymphocytes b
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
US20050203027A1 (en) * 2004-02-23 2005-09-15 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
HRP20212002T1 (hr) 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
WO2005105827A2 (fr) 2004-04-15 2005-11-10 Proteolix, Inc. Composes pour l'inhibition enzymatique
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US8088741B2 (en) 2004-05-10 2012-01-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
ATE553077T1 (de) 2004-07-23 2012-04-15 Nuada Llc Peptidaseinhibitoren
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006045066A2 (fr) 2004-10-20 2006-04-27 Proteolix, Inc. Composes pour inhibition d'enzymes
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
CA2595749A1 (fr) * 2005-01-27 2006-08-03 Research Development Foundation Therapie de combinaison avec des composes triterpenoides et des inhibiteurs de proteasome
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
NZ578297A (en) * 2005-02-16 2010-11-26 Anacor Pharmaceuticals Inc Boron-containing small molecules
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
BRPI0609861A2 (pt) * 2005-04-29 2010-05-11 Kosan Biosciences Inc uso de 17-aag ou 17-ag ou um pró-fármaco de ambos em combinação com um inibidor de proteassoma na preparação de formulações farmacêuticas para tratar mieloma múltiplo
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CA2613889A1 (fr) * 2005-06-08 2006-12-14 Centocor, Inc. Therapie cellulaire pour la degenerescence oculaire
EP1912664A2 (fr) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Utilisation d'un compose permettant d'ameliorer l'expression des proteines membranaires sur la surface d'une cellule
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
EP1752467A1 (fr) 2005-08-10 2007-02-14 4Sc Ag Inhibiteurs de la proliferation de cellules cancereuses, de cellules t, et de keratinocytes
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
RU2453556C2 (ru) 2005-11-09 2012-06-20 Протеоликс, Инк. Соединения для ингибирования фермента
WO2007067752A2 (fr) * 2005-12-08 2007-06-14 Cytokinetics, Inc. Compositions et procedes de traitement
EP1976536A4 (fr) 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc Petites molecules contenant du bore
JP5137849B2 (ja) * 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
SI1981874T1 (sl) * 2006-01-19 2009-10-31 Janssen Pharmaceutica Nv Aminofenilni derivati kot novi inhibitorji histon deacetilaze
AU2007206944B2 (en) * 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007206942B2 (en) * 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ME02188B (me) 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
CN101516375B (zh) * 2006-09-15 2012-10-03 詹森药业有限公司 类别-i具体组织蛋白脱乙酰基酶抑制剂与蛋白酶体抑制剂的组合
KR101489947B1 (ko) * 2006-09-15 2015-02-04 얀센 파마슈티카 엔.브이. 프로테아좀 억제제와 배합하여, ｉ－형 및 ｉｉｂ－형 히스톤 데아세틸라아제에 결합 활성을 나타내는 히스톤 데아세틸라아제 억제제
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CA2606634A1 (fr) * 2006-12-08 2008-06-08 Centenary Institute Of Cancer Medicine And Cell Biology Essai biologique repondant aux effets des inhibiteurs du proteasome
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA3114827C (fr) 2007-07-31 2023-09-05 Lifescan, Inc. Differenciation de cellules souches embryonnaires humaines de l'endocrine pancreatique
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
AU2007357338B2 (en) * 2007-08-06 2014-03-20 Takeda Pharmaceutical Company Limited Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20100051828A (ko) * 2007-09-12 2010-05-18 닥터 레디스 레보러터리즈 리미티드 보르테조밉 및 그의 제조방법
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
KR20170040374A (ko) 2007-10-04 2017-04-12 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2229434B1 (fr) 2007-11-27 2011-09-07 Lifescan, Inc. Différentiation des cellules souches embryonnaires humaines
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
EP2240475B1 (fr) 2007-12-20 2013-09-25 Novartis AG Dérivés de thiazole utilisés comme inhibiteur de la pi 3 kinase
KR101731474B1 (ko) 2008-02-21 2017-05-11 얀센 바이오테크 인코포레이티드 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물
CN102014927A (zh) * 2008-03-06 2011-04-13 安纳考尔医药公司 作为抗炎药的含硼的小分子
WO2009140309A2 (fr) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
CA2727862C (fr) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Composes de borates esters et compositions pharmaceutiques contenant des composes
PL2310492T3 (pl) 2008-06-30 2015-12-31 Janssen Biotech Inc Różnocowanie pluripotencjalnych komórek macierzystych
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
WO2010027975A1 (fr) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
MX349178B (es) * 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
PL2346988T3 (pl) 2008-10-31 2017-10-31 Janssen Biotech Inc Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
ES2584053T3 (es) * 2008-11-20 2016-09-23 Janssen Biotech, Inc. Métodos y composiciones para la unión de células y cultivo en sustratos planos
ES2642070T3 (es) 2008-11-20 2017-11-15 Janssen Biotech, Inc. Cultivo de células madre pluripotentes en microportadores
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
MX2011006334A (es) * 2008-12-17 2011-09-22 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
CN102292086B (zh) * 2009-01-09 2013-05-08 太阳医药高级研发有限公司 药物组合物
WO2010096574A1 (fr) 2009-02-20 2010-08-26 Lisanti Michael P Procédé de diagnostic ou de pronostic d'un néoplasme comprenant la détermination du taux d'expression d'une protéine dans des cellules stromales adjacentes au néoplasme
CN102369011A (zh) 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2010106135A1 (fr) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Utilisation combinée pour le traitement d'un carcinome ovarien
AU2010229988B9 (en) 2009-03-24 2015-09-17 Janssen Pharmaceutica Nv Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor
CN103932972A (zh) * 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
WO2010114768A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
WO2010114770A1 (fr) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
CA2763471A1 (fr) * 2009-05-27 2010-12-02 Cephalon, Inc. Polytherapie pour le traitement d'un myelome multiple
EP2280016A1 (fr) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boroniques aminés via des Alk-1-ynes substitués
WO2010146172A2 (fr) 2009-06-19 2010-12-23 Lek Pharmaceuticals D.D. NOUVELLE TECHNIQUE DE SYNTHÈSE POUR LA PRÉPARATION DE DÉRIVÉS D'ACIDE α-AMINOBORONIQUE PAR L'INTERMÉDIAIRE D'ALK-1-YNES SUBSTITUÉES
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
EP2270019A1 (fr) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. Nouvelle voie de synthèse pour la préparation d'esters boronique alpha-aminé
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
SG177483A1 (en) * 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
EP2456859A4 (fr) 2009-07-20 2015-03-18 Janssen Biotech Inc Différentiation de cellules souches embryonnaires humaines
KR102058901B1 (ko) 2009-07-20 2019-12-24 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011017125A1 (fr) * 2009-07-28 2011-02-10 Anacor Pharmaceuticals, Inc. Molécules contenant du bore trisubstitué
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
WO2011022337A1 (fr) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents anti-protozoaires
ES2557316T3 (es) 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (fr) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Supports et procédés pour traiter les conditions ischémiques
HUE032571T2 (en) * 2009-10-01 2017-09-28 Janssen Pharmaceutica Nv Proteasome inhibitors for treating cancer
WO2011049971A1 (fr) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore comme agents antiprotozoaires
US8461134B2 (en) * 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
AU2010341530B2 (en) * 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
SG181687A1 (en) 2009-12-23 2012-07-30 Centocor Ortho Biotech Inc Differentiation of human embryonic stem cells
CA2784425A1 (fr) 2009-12-23 2011-06-30 Centocor Ortho Biotech Inc. Differenciation de cellules souches embryonnaires humaines
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CA2791651C (fr) * 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Composes pour inhibition de l'immunoproteasome
EP2542667A4 (fr) 2010-03-01 2013-07-31 Janssen Biotech Inc Procédés de purification de cellules issues de cellules souches pluripotentes
NZ602392A (en) * 2010-03-18 2014-03-28 Innopharma Inc Stable bortezomib formulations
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2011116348A1 (fr) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Petites molécules borées en tant qu'agent anti-protozoaire
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8513218B2 (en) * 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
WO2011133479A2 (fr) 2010-04-19 2011-10-27 Niiki Pharma Inc. Polythérapie avec un inhibiteur du protéasome et un complexe de gallium
WO2011139379A2 (fr) 2010-05-06 2011-11-10 Duke University Méthode de traitement de patients suivant une thérapie de remplacement de protéine, une thérapie de remplacement de gène ou d'autres modalités thérapeutiques
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
ES2658146T3 (es) 2010-08-31 2018-03-08 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
EP2611907B1 (fr) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Différenciation de cellules souches pluripotentes
WO2012033858A2 (fr) 2010-09-07 2012-03-15 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
AU2011312264B2 (en) 2010-10-05 2015-07-02 Fresenius Kabi Usa, Llc Bortezomib formulations stabilised with boric acid
ES2548256T3 (es) 2010-10-14 2015-10-15 Synthon Bv Proceso para la preparación de bortezomib y los intermedios para el proceso
JP5963777B2 (ja) 2011-01-31 2016-08-03 ノバルティス アーゲー 新規ヘテロ環誘導体
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
WO2012135528A2 (fr) 2011-03-29 2012-10-04 Texas Tech University System Polythérapie par galectine-3c pour cancer humain
KR101869125B1 (ko) 2011-03-31 2018-06-19 나노캬리아 가부시키가이샤 보론산 화합물을 함유한 블록 공중합체를 포함하는 의약 조성물
CA2832109C (fr) 2011-06-10 2021-07-06 Oregon Health & Science University Glycoproteines de cmv et vecteurs recombinants cmv
US20140121182A1 (en) * 2011-06-22 2014-05-01 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
MX357429B (es) 2011-08-11 2018-07-09 Janssen Pharmaceutica Nv Predictores para el tratamiento del cáncer.
WO2013021032A1 (fr) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Inhibiteurs d'histone désacétylase en combinaison avec des inhibiteurs du protéasome et la dexaméthasone
PT2744332T (pt) 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
CN108383893A (zh) * 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
EP2771489B1 (fr) 2011-10-28 2018-07-04 Millennium Pharmaceuticals, Inc. Biomarqueurs de réponse à des inhibiteurs de nae
CA2855368A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite vis-a-vis d'inhibiteurs du proteasome
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
WO2013073697A1 (fr) 2011-11-17 2013-05-23 国立大学法人 東京大学 Copolymère séquencé dans lequel un groupe acide phénylboronique a été introduit, et utilisation de ce dernier
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
JP6215235B2 (ja) 2012-01-24 2017-10-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療方法
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
US10293048B2 (en) 2012-03-02 2019-05-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
HK1206058A1 (en) 2012-03-07 2015-12-31 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
CA2784240C (fr) 2012-03-27 2014-07-08 Innopharma, Inc. Formulations stables a base de bortezomib
KR20150009540A (ko) 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
AU2013271581B2 (en) 2012-06-08 2018-08-09 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
KR20150067175A (ko) * 2012-09-11 2015-06-17 시플라 리미티드 보르테조밉을 제조하기 위한 방법
WO2014055543A2 (fr) 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarqueurs et procédés pour prédire la réponse vis-à-vis d'inhibiteurs et leurs utilisations
WO2014072985A1 (fr) 2012-11-06 2014-05-15 Natco Pharma Limited Nouveaux dérivés d'acide boronique an tant qu'agents anticancéreux
EP2919786A4 (fr) 2012-11-16 2016-06-01 Shilpa Medicare Ltd Procédé de préparation de bortézomib cristallin
WO2014097306A1 (fr) 2012-12-21 2014-06-26 Natco Pharma Limited Forme polymorphe stable et pure du bortézomib
BR112015015770A2 (pt) 2012-12-31 2017-07-11 Janssen Biotech Inc cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
IN2013MU01431A (fr) 2013-04-16 2015-06-26 Cipla Ltd
WO2014172627A1 (fr) 2013-04-19 2014-10-23 Thomas Jefferson University Methodes associees a la caveoline-1 pour le traitement d'un glioblastome par temozolomide
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015003146A1 (fr) 2013-07-03 2015-01-08 Georgetown University Dérivés acide boronique de resvératrol pour l'activation des enzymes désacétylases
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
MX2016003979A (es) 2013-10-03 2016-06-15 Millennium Pharm Inc Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
WO2015076359A1 (fr) * 2013-11-21 2015-05-28 国立大学法人北海道大学 Compose inhibiteur du proteasome
EP3077823B1 (fr) * 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions et méthodes pour identifier et traiter la cachexie ou la pré-cachexie
SI3076969T1 (sl) 2013-12-06 2021-12-31 Novartis Ag Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
EP3102585B1 (fr) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Esters d'acide boronique et leurs formulations pharmaceutiques
EP2910557A1 (fr) * 2014-02-20 2015-08-26 Ikerchem, S.L. Pyrrolidines tétrasubstitués énantiopures en tant qu'échafaudages pour inhibiteurs de protéasome et ses applications médicinales
WO2015170757A1 (fr) 2014-05-08 2015-11-12 国立大学法人 東京大学 Composition pharmaceutique
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
WO2016022955A1 (fr) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
RU2017115191A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
WO2016110870A1 (fr) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Composition pharmaceutique de bortézomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
WO2016184793A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de traitement de patients souffrant d'un adénocarcinome rénal métastatique résistant aux inhibiteurs du vegfr
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120836A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
EP3120837A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
EP3389715A4 (fr) 2015-12-14 2019-06-12 David K. Thomas Compositions et procédés de traitement des dysfonctionnements cardiaques
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
DK3443073T3 (da) 2016-04-14 2024-09-02 Janssen Biotech Inc Differentiering af pluripotente stamceller til intestinale mellemtarmendodermceller
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (fr) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Formulations pharmaceutiques comprenant un complexe bortézomib-cyclodextrine
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
WO2018073790A1 (fr) 2016-10-20 2018-04-26 Pfizer Inc. Particules thérapeutiques avec des composés peptidiques d'acide boronique ou d'ester de boronate et leurs procédés de fabrication et d'utilisation
WO2018129533A1 (fr) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3583110A1 (fr) 2017-02-17 2019-12-25 Fresenius Kabi Oncology Ltd Procédé amélioré pour la préparation d'esters d'acide boronique
EP3589659B1 (fr) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinaisons pour utilisation dans le traitement du cancer
CN117338932A (zh) 2017-08-23 2024-01-05 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
JP2020533382A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
MA50906A (fr) 2017-11-16 2020-09-23 Principia Biopharma Inc Inhibiteurs d'immunoprotéasome
ES2928787T3 (es) * 2017-11-16 2022-11-22 Principia Biopharma Inc Inhibidores del inmunoproteasoma
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
JP2021512165A (ja) 2018-01-29 2021-05-13 コグノス・セラピューティクス・インコーポレイテッド ボルテゾミブの腫瘍内送達
WO2019178438A1 (fr) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
JP2020079299A (ja) * 2020-02-18 2020-05-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
CN114437119B (zh) * 2020-10-30 2024-08-09 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
US20240016815A1 (en) * 2020-12-02 2024-01-18 Hoffman Technologies Llc Compositions and methods for modulating cancer in non-human mammals
TWI906428B (zh) * 2020-12-10 2025-12-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
EP4134083A1 (fr) 2021-08-12 2023-02-15 Extrovis AG Compositions pharmaceutiques de bortézomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
WO2024097905A1 (fr) 2022-11-02 2024-05-10 Celgene Corporation Méthodes de traitement au moyen d'une thérapie par lymphocytes t et d'une thérapie d'entretien par agent immunomodulateur

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
DE3850574T2 (de) 1987-06-19 1994-10-27 Lucky Ltd Neue klasse von niedrigkalorischen proteinsüssstoffen.
EP0315574A3 (fr) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (fr) * 1990-09-24 1992-04-01 Unilever N.V. Composition détergente
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
CA2098609A1 (fr) * 1990-12-28 1992-06-29 Raymond T. Bartus Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
SK120993A3 (en) * 1991-04-30 1994-08-10 Procter & Gamble Liquid detergents with an aryl boronic acid
DK0583420T3 (da) * 1991-04-30 1996-07-29 Procter & Gamble Builderholdige flydende detergenter med borsyre-polyol-kompleks til inhibering af proteolytisk enzym
EP0511456A1 (fr) * 1991-04-30 1992-11-04 The Procter & Gamble Company Détergents liquides contenant un ester aromatique de l'acide borique pour inhibition d'enzyme protéolitique
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU4077193A (en) * 1992-04-16 1993-11-18 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
DE69314169T2 (de) * 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
EP0583536B1 (fr) * 1992-08-14 1997-03-05 The Procter & Gamble Company Compositions détergents liquides contenant de l'acide borique
EP0684829A4 (fr) 1993-02-10 1997-05-21 Harvard College Role de la proteolyse dependant de l'ubiquitine atp dans la presentation de l'antigene restreint chm-1 et inhibiteurs utilises a cet effet.
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
JP4162491B2 (ja) * 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
HRP20212002T1 (hr) * 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline

Also Published As

Publication number Publication date
US6548668B2 (en) 2003-04-15
DK1312609T3 (da) 2006-05-15
US7119080B2 (en) 2006-10-10
ATE314378T1 (de) 2006-01-15
EP0788360B3 (fr) 2009-08-12
US20150072942A1 (en) 2015-03-12
KR100398944B1 (ko) 2004-06-04
US5780454A (en) 1998-07-14
ES2199257T7 (es) 2010-03-31
DE69530936T2 (de) 2004-02-26
US20060122390A1 (en) 2006-06-08
NO2004004I2 (no) 2007-09-10
HK1002059A1 (en) 1998-07-31
IL133831A0 (en) 2001-04-30
ATE241631T1 (de) 2003-06-15
IL137726A0 (en) 2001-10-31
CN1168633A (zh) 1997-12-24
FI971746A0 (fi) 1997-04-23
DE122004000025I1 (de) 2004-09-30
DK0788360T3 (da) 2003-09-22
NO971929L (no) 1997-06-12
DE69530936D1 (de) 2003-07-03
NZ337211A (en) 2000-12-22
NO971929D0 (no) 1997-04-25
ES2254803T3 (es) 2006-06-16
EP1997823A1 (fr) 2008-12-03
ES2199257T3 (es) 2004-02-16
DE69534727D1 (de) 2006-02-02
CA2203936A1 (fr) 1996-05-09
EP1627880A1 (fr) 2006-02-22
MX9703063A (es) 1998-07-31
FI20041415L (fi) 2004-11-03
EP0788360A4 (fr) 1998-05-06
AU4139896A (en) 1996-05-23
LU91083I2 (fr) 2004-08-09
CA2496538A1 (fr) 1996-05-09
US6617317B1 (en) 2003-09-09
JPH10510245A (ja) 1998-10-06
US7531526B2 (en) 2009-05-12
EP1312609B1 (fr) 2005-12-28
US20090247731A1 (en) 2009-10-01
US20080132678A1 (en) 2008-06-05
DE122004000025I2 (de) 2006-09-07
EP1312609A1 (fr) 2003-05-21
EP0788360A1 (fr) 1997-08-13
US6297217B1 (en) 2001-10-02
US8378099B2 (en) 2013-02-19
AU710564C (en) 1996-05-23
CA2496538C (fr) 2011-08-02
IL115790A0 (en) 1996-01-19
DK1627880T3 (da) 2008-12-08
KR970706824A (ko) 1997-12-01
US20020173488A1 (en) 2002-11-21
EP1627880B1 (fr) 2008-10-15
US20030199561A1 (en) 2003-10-23
FI120974B (fi) 2010-05-31
HK1087714A1 (en) 2006-10-20
CN1305475C (zh) 2007-03-21
US20070282100A1 (en) 2007-12-06
ATE411324T1 (de) 2008-10-15
LU91083I9 (fr) 2018-12-28
NO2004004I1 (no) 2004-08-06
PT788360E (pt) 2003-10-31
AU710564B2 (en) 1999-09-23
US8003791B2 (en) 2011-08-23
WO1996013266A1 (fr) 1996-05-09
NO310558B1 (no) 2001-07-23
DE69534727T2 (de) 2006-09-14
TW318850B (fr) 1997-11-01
US20130310320A1 (en) 2013-11-21
NL300151I1 (nl) 2004-08-02
FR04C0014I1 (fr) 2004-09-17
IL133831A (en) 2004-03-28
IL115790A (en) 2002-12-01
ES2314540T3 (es) 2009-03-16
DE69535866D1 (de) 2008-11-27
US6747150B2 (en) 2004-06-08
EP0788360B1 (fr) 2003-05-28
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
FI114801B (fi) 2004-12-31
US6465433B1 (en) 2002-10-15
DE69530936C5 (de) 2007-02-22
US20040167332A1 (en) 2004-08-26
DE69530936T3 (de) 2010-08-26
CH0788360H1 (de) 2006-03-15
PT1627880E (pt) 2009-01-23
JP3717934B2 (ja) 2005-11-16
CA2203936C (fr) 2005-04-12
IL137726A (en) 2004-08-31
NZ296717A (en) 1999-11-29
PT1312609E (pt) 2006-05-31
US6083903A (en) 2000-07-04
NL300151I2 (nl) 2004-09-01
CY2484B1 (en) 2005-06-03
FI971746L (fi) 1997-06-06
US20110306560A1 (en) 2011-12-15
DK0788360T5 (da) 2017-09-18
US6066730A (en) 2000-05-23

Similar Documents

Publication Publication Date Title
FR04C0014I2 (fr)
ZA9610687B (en) Novel synthesis.
ZA9711092B (en) Novel compounds.
EP0669578A3 (fr) Schéma amélioré à cohérence ordonnée d'anti-mémoire.
ZA965505B (en) Novel compounds.
ZA957726B (en) 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives
EP0737314A4 (fr) Nouvelles utilisations de produits de recombinaison de recepteurs de gal4
EP0645391A3 (fr) Dérivés d'acide aminobenzoique.
PL340372A1 (en) Novel 3,6x-hemiketals of 9a-azalydes class
HU9400745D0 (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives
ZA966396B (en) Boronic acid derivatives.
ZA942880B (en) 2,6.disubstituted 4-quinolyl-dihydropridines
AU2618995A (en) Novel 3,5-dimethylpiperidin-1-ylalkyl esters
ZA965504B (en) Novel compounds.
AU9102991A (en) 2,6-methano-2h-1-benzoxocincarboxamides as 5-ht3-antagonists
ZA941734B (en) 2,4-diamino-3-hydroxycarboxylic acid derivatives
ZA975696B (en) Novel compounds.
ZA97415B (en) Novel compounds.
GB9326343D0 (en) Novel catalyst composition